Targeted, Quantitative Protein Assays & Panels
Get the Resource
Download NowAccurate, quantitative protein assays are critical to advancing drug development, enabling confident translation of key targets and biomarkers identified in early studies. With Sapient’s mass spectrometry-based targeted assays, we can measure the proteins that matter most to your study – precisely, quantitatively, and at scale.
What differentiates Sapient's quantitative protein assays?
Unlike traditional antibody-based approaches, our methods do not rely on antibodies or binding agents, which not only saves assay development time but also eliminates challenges of non-specific binding and cross-reactivity. Our protein measures leverage labeled peptides for direct, absolute quantitation of proteins of interest in virtually any sample matrix, from plasma/serum to tissues, tumors, CSF, urine, saliva, eye fluids, cells, and media for both human and preclinical studies.
This specificity also allows us to measure measure specific protein isoforms, non-canonical protein variants, and post-translational modifications (PTMs) that may represent biologically meaningful targets or biomarkers. In addition to endogenous proteins of interest, our workflows also enable measure of viral proteins, bacterial proteins, and drug levels.
What specific targeted assays are offered?
Sapient offers >12,000 off-the-shelf protein assays that have already been measured through our mass spectrometry-based workflows. Any of these can undergo further qualification as a quantitative protein assay based on your specific study, sample type, and context of use (COU) statements, including with absolute quantification.
We can also develop bespoke assays for difficult-to-measure proteins outside of our existing menu. Protein measures can also be customized in multiplexed panels, with high-throughput analysis ideal for detecting and monitoring protein targets and biomarkers in large-scale population studies and clinical trials.
Download the fact sheet to see how we can deliver quantitative protein assays with rapid turnaround for nearly any sample type, and how Sapient’s mass spectrometry-based approach delivers added benefits relative to traditional approaches such as ligand binding assays by:
- Eliminating time-consuming steps required to develop and optimize detection antibodies
- Negating challenges of non-specific binding and cross-reactivity
- Enabling measure of specific protein isoforms, variants, and PTMs
- Providing for measure across diverse sample matrices and species
- Allowing for multiplexing with custom-built panels
- Enabling delivery of protein measures at scale, with high throughput mass spectrometry systems to process hundreds of samples per day
Our targeted protein assays and panels support the rapid delivery of precise data and robust insights that inform and accelerate all phases of drug development – from target identification to pharmacokinetic (PK) / pharmacodynamic (PD) / target engagement (TE) studies and clinical biomarker monitoring.